NASDAQ: ADUS · Medical Care Facilities
Addus HomeCare (ADUS) fair value: undervalued or overvalued?
As of 14 Nov 2026, Faircurve's model values Addus HomeCare (ADUS) at $133.49 a share. The stock last closed at $124.61, which puts the model's fair value 7.1% above the price. On the model's bands that reads as Fairly valued.
Revalued . Price is the close of 16 Nov 2026. Addus HomeCare Corporation.
The report adds the live price, the chart against the range the options market prices, the next earnings date and the analysts' consensus. No account needed.
This week, in three parts
What happenedThe run of 14 Nov 2026 held the fair value at $133.49, within 1% of the run of 7 Nov 2026.
What the model makes of itThe price of $124.61 is 7.1% below it: Fairly valued, on a medium evidence grade.
What's nextNext report on 22 Feb 2027. Options prices imply a move of about 10% either way over the next month. The next weekly run is on Saturday 21 Nov 2026.
What price range does the model give ADUS?
The calibrated range for ADUS over 63 trading days is $111.79 to $139.67. It sits around the last close, and its width comes from the volatility that ADUS's own options imply (33% a year), calibrated weekly against realised prices (n = 8,038 past valuations, refreshed 14 Nov 2026). Ranges built this way held the price 60% of the time at this horizon. The fair value is the model's opinion and rides beside the range. It is not the centre of it.
The model's own simulated range, from the 20th to the 80th percentile of its runs, is $99.18 to $177.87. In 59% of the simulations the fair value came out above the price the model ran on.
Faircurve Insights · 14 Nov 2026
Addus HomeCare Corporation (ADUS) is a healthcare company in the medical care facilities group. Through its various subsidiaries, it offers essential personal support services across the United States.
Faircurve's model put the fair value of Addus HomeCare Corporation at $133.49 a share on 14 Nov 2026, the midpoint of 2,000 simulations. The previous run, on 7 Nov 2026, gave $134.13, and the fair value moved -0.5%. The calibrated range over 63 trading days is $112.35 to $135.27. It is built around the price from the volatility the stock's own options imply. Ranges built this way held the price 60% of the time at this horizon. The model grades the evidence as Medium. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say whether the fair value is right.
Addus scores 73 out of 100 on the model's overall quality measure, a composite of six quality factors scored against comparable companies. Stability scores 100, with EBITDA margin downside volatility over 5y at 0.6 pts against a peer median of 2.2 pts. Balance sheet scores 90, with net debt / EBITDA at -0.18x against a peer median of 2.45x. Earnings quality scores 88, with FCF / net income at 1.28x against a peer median of 1.06x. The model compares the company with Healthcare Services Group, Inc. (HCSG), U.S. Physical Therapy, Inc. (USPH) and Hims & Hers Health, Inc. (HIMS).
Written from the figures on this page for the 14 Nov 2026 valuation and checked by rule before publishing: every number is one printed here, no forecast, no instruction. The price, the gap and the verdict are the page's own and change daily. Not a recommendation.
The Global Pulse
Faircurve's note after each US session, in your inbox. No account needed.
When does ADUS report earnings, and how has the stock reacted?
Addus HomeCare's next earnings report is scheduled for 22 Feb 2027. Companies can move their dates.
Options prices on 16 Nov 2026 imply a move of about 7.6% in either direction through the nearest expiry, about 31 days out. That is the size the market is pricing, not a direction. ADUS's 30 day implied volatility works out to about 9.5% over one month.
Around its last 8 reports: what the options market priced, and what followed
Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across ADUS's last 8 reports, ignoring direction, was 2.9%.
What the options market has priced for a month's move in ADUS
How does ADUS score on business quality?
Addus HomeCare's overall quality score is 73 out of 100. Each factor below is a score against comparable companies, not a percentile of the metric beside it.
| Factor | Score (0 to 100) | Headline measure | Peer median |
|---|---|---|---|
| ProfitabilityReturn on invested capital against the peer group, with a bonus for an improving trend. | 55 | 10.0%ROIC | 13.4% |
| Earnings qualityHow much of reported profit is cash: free cash flow to net income, and the accrual ratio (the share of earnings that is not cash). | 88 | 1.28xFCF / net income | 1.06x |
| Growth qualityTrailing revenue growth, forward growth from consensus, and the direction of analysts' rating changes. | 66 | 23.2%Revenue growth, trailing | 18.6% |
| Capital disciplineReinvestment efficiency (capital spending per unit of revenue) and net buybacks. | 63 | 0.0%Net buybacks / market value | 0.2% |
| Balance sheetNet debt to EBITDA and interest coverage. | 90 | -0.18xNet debt / EBITDA | 2.45x |
| StabilityDownside volatility of the EBITDA margin over the last five years. | 100 | 0.6 ptsEBITDA margin downside volatility, 5y | 2.2 pts |
How does ADUS compare with similar companies?
The companies in medical care facilities closest to Addus HomeCare in market value, each on the same model and the same date.
| Company | Last close | Model fair value | Gap | Model verdict |
|---|---|---|---|---|
| MD Pediatrix Medical Group, Inc. | $31.89 | $35.38 | +10.9% | Low evidence grade |
| HCSG Healthcare Services Group, Inc. | $24.86 | $24.39 | -1.9% | Fairly valued |
| NHC National HealthCare Corporation | $207.19 | $249.00 | +20.2% | Low evidence grade |
| ASTH Astrana Health, Inc. | $32.87 | $38.40 | +16.8% | Low evidence grade |
| ACHC Acadia Healthcare Company, Inc. | $38.70 | $44.44 | +14.8% | Low evidence grade |
| USPH U.S. Physical Therapy, Inc. | $99.55 | $92.36 | -7.2% | Fairly valued |
| AMN AMN Healthcare Services, Inc. | $39.64 | $43.14 | +8.8% | Low evidence grade |
| HIMS Hims & Hers Health, Inc. | $18.56 | $21.46 | +15.6% | Undervalued |
What the comparable companies' multiples alone would give for ADUS, the peer-implied price, is $190.88 a share on this run. The fair value weighs that against the company's own multiple.
All medical care facilities stocks ranked by gap to fair value
Addus HomeCare at a glance
Addus HomeCare Corporation, through its various subsidiaries, offers essential personal support services across the United States.
- Market value
- $2.3B
- Sector
- Healthcare
- Industry
- Medical Care Facilities
- Revenue expected, next twelve months
- $1.6B
- Consensus revenue growth, next fiscal year
- +7.1%
- Analysts with estimates
- 9
- Beta to the US market
- -0.06
- First valued by Faircurve
- 11 Jul 2026
At the close of 16 Nov 2026, 56.8% of the 1,085 graded US stocks the model covers traded below the model's fair value. ADUS was among them.
How the fair value is worked out: the model prices Addus HomeCare on the value of the whole business, debt included, against the operating profit analysts expect next year (forward EV/EBITDA), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.
What changed in the latest valuation?
On 7 Nov 2026 the model's fair value for ADUS was $134.13. As of 14 Nov 2026 it is $133.49, a change of -0.5%. The model revalues every stock it covers each week, and again after an earnings report.
Questions about Addus HomeCare's valuation
Is Addus HomeCare stock undervalued or overvalued?
On Faircurve's model, ADUS reads as Fairly valued as of 14 Nov 2026. The model's fair value is $133.49 a share against a last close of $124.61, a gap of +7.1%.
What is ADUS's fair value?
$133.49 a share as of 14 Nov 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $99.18 to $177.87.
What price range does the model give ADUS?
$111.79 to $139.67 over 63 trading days. Ranges built this way held the price 60% of the time across 8,038 past valuations, refreshed 14 Nov 2026.
When does Addus HomeCare report earnings next?
The next report is scheduled for 22 Feb 2027. Companies can move their dates.
How much has ADUS moved on past earnings reports?
Across its last 8 reports the median two session move was 2.9%, ignoring direction. The largest was +11.1% around the report of 4 Aug 2025.
How confident is the model in this valuation?
The model's evidence grade for ADUS is medium. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.
The model's own ideas on ADUS
The model holds no idea open on ADUS today. Signed-in readers see the rule each idea runs on, the floor and the exit level the model set and its time limit, and the model's closed ideas on ADUS with their outcomes. A free account is enough.